SNM is working with the International Partnership for Critical Markers of Disease to host a meeting May 1 in Bethesda, Md., that will address the FDA prerequisites for PET radiopharmaceuticals production. SNM President-elect Michael Graham urged the scientific community to collaborate to advance personalized medicine that uses new imaging methods and radiopharmaceuticals to enable disease localization and treatment monitoring.

Related Summaries